Literature DB >> 15333787

Changes in the reproductive system of male mice immunized with a GnRH-analogue conjugated to mycobacterial hsp70.

S G Hannesdóttir1, X Han, T Lund, M Singh, R Van Der Zee, I M Roitt, P J Delves.   

Abstract

Immunosterilization is an attractive alternative to surgical castration. Gonadotropin-releasing hormone (GnRH) controls the production of the gonadotropins thereby having an orchestrating effect on the reproductive hormone cascade and spermatogenesis. Induction of neutralizing antibody can abrogate the effect of the hormone. Current GnRH-based vaccines often require strong adjuvants and/or multiple injections of the vaccines to overcome variability in the response. Heat shock proteins (hsp) have been used as carrier molecules because of their powerful intrinsic ability to enhance an immune response to associated antigens. A GnRH-analogue, GnRH-d6-Lys, was conjugated to recombinant Mycobacterium tuberculosis hsp70. Male BALB/c mice were immunized i.p. with GnRH-hsp70 in the mild adjuvant Ribi or in incomplete Freund's adjuvant (IFA). The initial immunizations were done on pre-pubertal 3-week-old mice, with boosts at 5 and 8 weeks of age. The mice were killed at 10 weeks of age and GnRH-specific antibodies and serum testosterone levels measured. All the immunized mice mounted GnRH-specific antibody responses, with no difference in the mice immunized with GnRH-hsp70/Ribi or with GnRH-hsp70/IFA. There was substantial atrophy of the urogenital complex and significantly (P < 0.0005) reduced levels of testosterone-dependent testicular relaxin-like factor mRNA expression. Mice immunized with GnRH-hsp70/Ribi showed substantially reduced (P < 0.001) serum testosterone levels. These results indicate that hsp70 may serve as a particularly advantageous carrier for GnRH-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333787     DOI: 10.1530/rep.1.00108

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  5 in total

1.  Investigation of factors influencing the immunogenicity of hCG as a potential cancer vaccine.

Authors:  N Kvirkvelia; N Chikadze; J Makinde; J D McBride; N Porakishvili; F A Hills; P M Martensen; J Justesen; P J Delves; T Lund; I M Roitt
Journal:  Clin Exp Immunol       Date:  2018-05-07       Impact factor: 4.330

2.  The hinge region fragment of immunoglobulin G improves immunogenicity of recombinant gonadotrophin-releasing hormone conjugated to the T-helper epitope in designing peptide vaccines.

Authors:  Jinshu Xu; Jie Wu; Xuejun Wang; Yin Zhang; Wenjia Li; Zheng Zhu; Dongya Zhu; Zhuoyi Hu; Rouel S Roque; Jingjing Liu
Journal:  Immunology       Date:  2008-11-24       Impact factor: 7.397

3.  Intraperitoneal administration of gonadotropin-releasing hormone-PE40 induces castration in male rats.

Authors:  Li Yu; Zhong-Fang Zhang; Chun-Xia Jing; Feng-Lin Wu
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

Review 4.  Immunocontraceptives: new approaches to fertility control.

Authors:  Kiranjeet Kaur; Vijay Prabha
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

5.  Brucella abortus RB51 ΔleuB expressing Salmonella FliC conjugated gonadotropins reduces mouse fetal numbers: A possible feral swine brucellosis immunocontraceptive vaccine.

Authors:  Steven G Waldrop; Garrett P Smith; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  Heliyon       Date:  2021-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.